Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 2
2010 2
2011 1
2012 9
2013 10
2014 7
2015 3
2016 5
2017 4
2018 10
2019 8
2020 6
2021 9
2022 12
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.
Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, Harke NN, Debus J, Koerber SA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Seibold P, Kristiansen G, Hadaschik B, Arsov C, Schimmöller L, Giesel FL, Antoch G, Makowski M, Wacker F, Schlemmer HP, Kaaks R, Albers P. Krilaviciute A, et al. Among authors: arsov c. Eur Urol Oncol. 2023 Dec;6(6):566-573. doi: 10.1016/j.euo.2023.09.008. Epub 2023 Oct 6. Eur Urol Oncol. 2023. PMID: 37806841
[Risk-adapted prostate cancer screening-update 2021].
Al-Monajjed R, Arsov C, Albers P. Al-Monajjed R, et al. Among authors: arsov c. Urologe A. 2021 May;60(5):592-601. doi: 10.1007/s00120-021-01505-9. Epub 2021 Apr 1. Urologe A. 2021. PMID: 33792743 Review. German.
[PSA screening and molecular markers].
Lakes J, Arsov C. Lakes J, et al. Among authors: arsov c. Urologe A. 2019 May;58(5):486-493. doi: 10.1007/s00120-019-0900-y. Urologe A. 2019. PMID: 30874831 Review. German.
[Prostate cancer screening: controversies and suggested solutions].
Al-Monajjed R, Arsov C, Albers P. Al-Monajjed R, et al. Among authors: arsov c. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Dec;61(12):1544-1550. doi: 10.1007/s00103-018-2840-x. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018. PMID: 30397721 Review. German.
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Boschheidgen M, Albers P, Schlemmer HP, Hellms S, Bonekamp D, Sauter A, Hadaschik B, Krilaviciute A, Radtke JP, Seibold P, Lakes J, Arsov C, Gschwend JE, Herkommer K, Makowski M, Kuczyk MA, Wacker F, Harke N, Debus J, Körber SA, Benner A, Kristiansen G, Giesel FL, Antoch G, Kaaks R, Becker N, Schimmöller L. Boschheidgen M, et al. Among authors: arsov c. Eur Urol. 2024 Feb;85(2):105-111. doi: 10.1016/j.eururo.2023.09.027. Epub 2023 Oct 18. Eur Urol. 2024. PMID: 37863727
Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial.
Krilaviciute A, Albers P, Lakes J, Radtke JP, Herkommer K, Gschwend J, Peters I, Kuczyk M, Koerber SA, Debus J, Kristiansen G, Schimmöller L, Antoch G, Makowski M, Wacker F, Schlemmer H, Benner A, Giesel F, Siener R, Arsov C, Hadaschik B, Becker N, Kaaks R. Krilaviciute A, et al. Among authors: arsov c. Int J Cancer. 2023 Mar 1;152(5):854-864. doi: 10.1002/ijc.34295. Epub 2022 Oct 5. Int J Cancer. 2023. PMID: 36121664 Free article. Clinical Trial.
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.
Arsov C, Becker N, Hadaschik BA, Hohenfellner M, Herkommer K, Gschwend JE, Imkamp F, Kuczyk MA, Antoch G, Kristiansen G, Siener R, Semjonow A, Hamdy FC, Lilja H, Vickers AJ, Schröder FH, Albers P. Arsov C, et al. Eur Urol. 2013 Dec;64(6):873-5. doi: 10.1016/j.eururo.2013.05.022. Epub 2013 May 14. Eur Urol. 2013. PMID: 23707067 Clinical Trial. No abstract available.
81 results